Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine

Joris van de Haar^#^{1

2}, Louisa Hoes^#^{1

2}, Emile Voest^{1

2}

Affiliations

¹ Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
² Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands.

^# Contributed equally.

Editorial

Joris van de Haar et al. ESMO Open. 2019.

. 2019 Apr 20;4(2):e000516.

doi: 10.1136/esmoopen-2019-000516. eCollection 2019.

Joris van de Haar^#^{1

2}, Louisa Hoes^#^{1

2}, Emile Voest^{1

2}

¹ Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
² Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands.

^# Contributed equally.

No abstract available

Keywords: genomics; molecular tumour board; oncology; precision oncology.

Conflict of interest statement

Competing interests: None declared.

Prospective analysis of 895 patients on a UK Genomics Review Board.
Moore DA, Kushnir M, Mak G, Winter H, Curiel T, Voskoboynik M, Moschetta M, Rozumna-Martynyuk N, Balbi K, Bennett P, Forster M, Kulkarni A, Haynes D, Swanton C, Arkenau HT. Moore DA, et al. ESMO Open. 2019 Mar 21;4(2):e000469. doi: 10.1136/esmoopen-2018-000469. eCollection 2019. ESMO Open. 2019. PMID: 31245058 Free PMC article.

1. Zehir A, Benayed R, Shah RH, et al. . Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017;23:703–13. 10.1038/nm.4333 - DOI - PMC - PubMed
1. Gray SW, Hicks-Courant K, Cronin A, et al. . Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol 2014;32:1317–23. 10.1200/JCO.2013.52.4298 - DOI - PMC - PubMed
1. van der Velden DL, van Herpen CML, van Laarhoven HWM, et al. . Molecular tumor boards: current practice and future needs. Ann Oncol 2017;28:3070–5. 10.1093/annonc/mdx528 - DOI - PubMed
1. Basse C, Morel C, Alt M, et al. . Relevance of a molecular tumour board (Mtb) for patients' enrolment in clinical trials: experience of the Institut Curie. ESMO Open 2018;3:e000339 10.1136/esmoopen-2018-000339 - DOI - PMC - PubMed
1. Dalton WB, Forde PM, Kang H, et al. . Personalized medicine in the oncology clinic: implementation and outcomes of the Johns Hopkins molecular tumor board. JCO Precis Oncol 2017;2017 10.1200/PO.16.00046 - DOI - PMC - PubMed